Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients
By Shaji K. Kumar, A. Dispenzieri, M. Lacy, M. Gertz, F. Buadi, Shivlal Pandey, P. Kapoor, D. Dingli, S. Hayman, N. Leung and 6 more. Leukemia, 2013
1,316 citations recorded by the source corpus.
Therapy for multiple myeloma (MM) has markedly changed in the past decade with the introduction of new drugs, but it is not clear whether the improvements have been sustained. We studied 1038 patients diagnosed between 2001 and 2010, grouping patients into two 5-year periods by diagnosis, 2001–2005 and 2006–2010. The median estimated follow-up for the cohort was 5.9 years with 47% alive at the last follow-up. The median overall survival (OS) for the entire cohort was 5.2 years: 4.6 years for patients in the 2001–2005 group compared with 6.1 years for the 2006–2010 cohort (P=0.002). The improvement was primarily seen among patients over 65 years, the 6-year OS improving from 31 to 56%, P<0.001. Only 10% of patients died during the first year in the latter group, compared with 16% in the earlier cohort (P<0.01), suggesting improvement in early mortality. The improved outcomes were linked closely to the use of one or more new agents in initial therapy. The current results confirm continued survival improvement in MM and highlight the impact of initial therapy with novel agents. Most importantly, we demonstrate that the improved survival is benefitting older patients and that early mortality in this disease has reduced considerably.
Subfields: Hematology, Molecular Biology, Oncology
View Paper: https://www.semanticscholar.org/paper/8e598b84d88acccdc07b77d7dc64ee4cfe2aee64
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Hematology
In Molecular Biology
In Oncology
Citations in the corpus
- Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma. (2016, neutral): “Insomnia 73 (20) 7 (2) 0 98 (27) 11 (3) 0”
- Anti‐BCMA CAR T‐Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma (2019, neutral): “Neurologic toxic effect§ 14 (42) 0 1 (3)”
- Multiple myeloma: 2020 update on diagnosis, risk‐stratification and management (2020, background): “Survival in multiple myeloma has improved significantly in the last 15 years.(49) The initial impact came from the introduction of thalidomide,(50) bortezomib,(51) and lenalidomide.”
- Multiple myeloma: 2022 update on diagnosis, risk stratification, and management (2022, background): “Survival in multiple myeloma has improved significantly in the last 15 years.(55) The initial impact came from the introduction of thalidomide,(56) bortezomib,(57) and lenalidomide.”